Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2015

View Archived Issues

TaiRx starts phase I trial of oral anticancer drug TRX-818

Blood cytokine biomarker signature detects tuberculosis and identifies dormant/active forms

Merck & Co. initiates phase I trial of MK-8591 for HIV-1 infection

Otonomy receives IND application clearance for tinnitus candidate OTO-311

VIS-410 shows activity and reduced duration of symptoms in phase IIa challenge study

Turing Pharmaceuticals files IND for TUR-004

Temsirolimus in recurrent bladder cancer treatment

ContraVir reports preliminary data for tenofovir prodrug in HBV

Proenkephalin plasma levels linked to CKD incidence

Ribociclib and binimetinib in combination for NRAS-mutant melanoma

Insero Health merges into Biscayne Pharmaceuticals

BARDA awards contract to Stratatech for StrataGraft skin substitute

Biosimilar ONS-1045 meets primary and secondary endpoints in phase I trial

SanBio starts phase II trial of stem cell therapy SB-623 in traumatic brain injury

RAD-1901: hybrid SERM/SERD active in breast cancer-derived brain metastasis models

Axovant Sciences begins phase III MINDSET study

Novel DYM mutations related to rare Dyggve-Melchior-Clausen syndrome

Vitamin B12 deficiency linked to diabetic cardiovascular autonomic neuropathy

Merck & Co. reports TrkA inhibitors

Janssen discloses c-Ros-1 inhibitors

Beijing Hanmi patents ROR-gamma modulators

Synta Pharmaceuticals HSP90-targeted SDC-TRAPs

Chungnam National University introduces cardiac myosin activators

Tarix Orphan receives FDA fast track designation for TXA-127 in DMD

Akebia reaches agreement with FDA and EMA on phase III program for vadadustat

Genzyme completes acquisition of vandetanib from AstraZeneca

FDA places clinical hold on axalimogene filolisbac

Guadecitabine receives FDA orphan drug designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...